Next to the well-known pro-tumorigenic characteristics of ADAM17, it was demonstrated that in cervical cancer, expression of ADAM17 is actually required for the HPV entry platform assembly via CD9, transforming growth factor alpha (TGFα), and phosphorylated mitogen-activated protein kinase 1 (MAPK1/ERK) (46). Here, ADAM17 is linked to cervical carcinoma.